gastrointestinal disorder News
-
Atmo featured on Medical Director’s Healthtech Showcase
Atmo Biosciences CEO Mal Hebblewhite was invited to present at Medical Director’s Healthtech Showcase. In the video below, Mal gives an overview of Atmo Biosciences then talks to showcase host Dominique Powis about Atmo’s journey so far, and how its ingestible gas-sensing capsule can improve diagnosis and treatment for common gastrointestinal disorders. ...
-
Showcase
Atmo Biosciences awarded Australian Government grant to automate and scale-up manufacturing of ingestible gas-sensing capsule
Atmo Biosciences has been awarded an Australian Government Manufacturing Modernisation Fund (MMF) grant to support manufacturing automation and scale-up for the Atmo Gas-Sensing Capsule. The Round 2 MMF grants, part of the Government’s Modern Manufacturing Strategy, are for small-medium sized businesses to transform manufacturing and to support job growth and develop a more skilled ...
-
Posters Presented at DDW 2022 Demonstrate G-Tech System Motility Measurements Correlate with Antroduodenal Manometry Measurements and Can be Used to Characterize Colon Motility Alteration
MOUNTAIN VIEW, Calif., May 26, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced that two posters were presented at Digestive Disease Week Conference held in San Diego in from May 21 through May 24. The first poster, entitled Wireless non-invasive patches detect phase III of the migrating motor complex in ...
-
Atmo Biosciences signs deal with RMIT University to commercialize ingestible gas-sensing capsule for gut health
Atmo Biosciences has signed a licensing deal with RMIT University securing the exclusive worldwide rights to commercialize a ground-breaking ingestible gas-sensing capsule. The Atmo Gas Capsule is set to revolutionize how doctors diagnose and treat common gastrointestinal (GI) disorders by offering a non-invasive, low-cost, and more accurate alternative to current technologies. Patients with ...
-
G-Tech Medical Receives FDA Clearance for its Gastrointestinal Motility Monitoring System
MOUNTAIN VIEW, Calif., January 13, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Wireless Patch System (WPS) for non-invasive myoelectric activity measurement. The G-Tech WPS is a tool that provides gastric and intestinal myoelectrical ...
-
Atmo Biosciences secures $9.6 million in oversubscribed capital raise
Atmo Biosciences has closed a successful, oversubscribed A$9.6m capital raise. The raise was led by two new, cornerstone investors – Sydney-based investment firm Alium Capital Management and Japanese multinational company Otsuka Pharmaceutical. The funding will enable Atmo to accelerate product development of its gas-sensing capsule, which detects clinically important gaseous biomarkers ...
-
EvoEndo Raises $10.1 Million to Make Unsedated Transnasal Endoscopy a Reality for Patients and Physicians
EvoEndo Inc., (“EvoEndo” or “the Company”) a preclinical medical device company developing systems for unsedated Transnasal Endoscopy (TNE), announced it has secured $10.1M in equity financing. The funding round, which included a variety of family offices and early-stage life science investors, will be used to further EvoEndo’s innovative technology designed to help ...
By EvoEndo
-
Hansoh Expands AI Partnership with Atomwise after Early Success for Key Target in Therapy-Evading Cancers
Hansoh Pharma (3692:HK), a leading biopharmaceutical company in China, and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the expansion of their strategic partnership for AI-accelerated drug discovery. Expansion of the partnership immediately follows completion of their first hit-discovery collaboration, which successfully identified and experimentally ...
-
Atlantic Healthcare plc acquires global rights to renzapride for the treatment of gastrointestinal motility disorders
Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases, today announced that the Company has entered into an agreement to acquire the global rights to renzapride from EndoLogic LLC (“EndoLogic”). Renzapride is a ...
-
Symberix Awarded Multiple Grants from National Institutes of Health to Expand Platform of Microbiome-Targeted Drugs
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH). The two SBIR grants collectively totaling over $1.5 million are awarded by the NIH’s National Center for Advancing Translational ...
-
AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema
AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company’s Ammonia ...
-
Symberix Announces Non-Dilutive Funding Support for Lead Programs
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded three Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), entered into a Research Collaboration Agreement with the NIH’s National Center for Advancing Translational Sciences (NCATS), and ...
-
Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis
Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced a $112 million Series C financing. This financing will be used to advance its portfolio of programs and the company’s first clinical trials, further establishing its leadership in the gut-brain axis field. All investors from the Series ...
-
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease
Preliminary data showed that isaralgagene civaparvovec, or ST-920, was generally well tolerated All four patients in the first two dose cohorts exhibited above normal α-Gal A activity, which was maintained for up to one year for the first patient treated Based on these data, Sangamo has initiated Phase 3 planning The fifth patient was recently dosed, in the third dose cohort Q3 ...
-
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease
Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients In the first two dose cohorts, all four patients exhibited above normal α-Gal A activity, ranging from 3-fold to 15-fold above mean normal; patients in the first dose cohort have maintained elevated activity for one year and are now in the long-term ...
-
Cairn Diagnostics Delivers Virtual Administration of its Novel 13C-Spirulina Gastric Emptying Breath Test
Cairn Diagnostics, an innovative leader in providing cutting-edge breath tests intended for routine use in diagnostic medicine, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of the Company’s 13C-Spirulina Gastric Emptying Breath Test (GEBT) to now include “at home” administration under virtual supervision of Cairn Diagnostics. GEBT ...
-
Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND
SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that the U.S. Food and Drug Administration (FDA) has ...
-
Creative Enzymes Probiotics Expands Service Offering with the Launch of Bifidobacterium Strains
Creative Enzymes, a professional and experienced supplier of enzymes, has a great reputation in the industry. With the continuous expansion of business areas and scale, the company has set foot in other areas and established a sound probiotic production and supply chain. The product manager of the Probiotics division is excited to announce the launch of Bifidobacterium strains to support your ...
-
FDA Knew Devices Spread Fatal `Superbug`
U.S. health regulators have known since at least 2009 that the medical devices at the center of the "superbug" outbreak at UCLA can transmit lethal infections but have not recommended any new safety requirements, a lapse that threatens patient safety, experts in hospital-acquired infections said. The latest outbreak involving the reusable devices called duodenoscopes, which are inserted down the ...
-
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs
SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by approximately 20%. This ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you